Less than a tenth of patients eligible to benefit from obesity jabs like Wegovy are able to get them, caution the World Health Organization as it publishes its inaugural guidance on the therapies.
With in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging broader and more equitable access to GLP-1 medication.
According to forecasts, over two billion will be living with obesity by 2030 without intervention.
"Our latest guidance affirms that excess weight is a lifelong illness that can be managed with holistic and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are key obstacles to broad access to the treatments that can help people shift considerable weight, notes the organization.
Skinny Jab Shortage
Even under the current best projected case, the manufacturing of such drugs could only cover approximately 100 million people – less than 10% of eligible patients, per the WHO.
The guideline calls on nations and manufacturers to widen availability, through approaches such as patent sharing.
A patent on a key compound – the main ingredient of Novo Nordisk's Wegovy – is set to lapse in several nations in 2026.
The Way Obesity Drugs Operate
GLP-1 drugs imitate a biological compound to reduce digestion speed, curb appetite and increase satiety so individuals reduce food intake.
People commonly see weight reduction after several weeks of starting on the regular doses.
Studies suggests patients may see weight return a year later of halting the medication, because their normal hunger resume.
To be carrying excess weight elevates your likelihood for contracting health problems, like diabetes, heart disease, brain attack, and some malignancies.
Obesity impacts people in every country and was linked to 3.7 million fatalities worldwide in 2024, according to the WHO.
